MIS 416

Drug Profile

MIS 416

Alternative Names: MIS-416

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Virionyx
  • Developer Innate Immunotherapeutics
  • Class
  • Mechanism of Action Immunomodulators; NOD2 protein modulators; Toll-like receptor 9 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • No development reported Cancer; Infections

Most Recent Events

  • 01 Jun 2017 Innate Immunotherapeutics completes a phase II trial in Multiple sclerosis in New Zealand and Australia (IV) (NCT02228213)
  • 22 Apr 2017 Pharmacodynamics data from a phase I/II trial and preclinical study in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top